<DOC>
	<DOCNO>NCT00854841</DOCNO>
	<brief_summary>Research Hypothesis : Treatment dasatinib 100 mg QD superior imatinib 600 mg QD term complete cytogenetic response ( CCyR ) chronic phase ( CP ) Philadelphia chromosome-positive ( Ph+ ) Chronic Myeloid Leukemia ( CML ) subject imatinib failure achieve suboptimal response 3-18 month ( 12-77 week ) therapy imatinib 400 mg. Primary Objective : The primary objective study compare rate CCyR dasatinib ( 100mg QD ) high-dose imatinib ( 600 mg QD ) therapy 6 month randomization CP Ph+ CML subject imatinib failure achieve suboptimal response 3 - 18 month imatinib monotherapy 400 mg/day .</brief_summary>
	<brief_title>The Randomized Study Dasatinib High-Dose Imatinib ( 600mg ) Suboptimal Responder</brief_title>
	<detailed_description>Study Design : Prospective open-label , randomize two arm , multicenter study patient suboptimal response standard Tx evaluate efficacy &amp; safety dasatinib ( 100mg qd ) &amp; imatinib ( 600mg daily ) CyR &amp; MoR 3 , 6 &amp; 12 month . - Randomized 1:1 - Crossover alternate permit confirm PD 3M ( AP , BC &amp; loss CHR MCyR ) &amp; absence response 6M . Duration Study : Subjects treat 12 month , unless disease progression unacceptable toxicity occur , subject withdraws , study discontinue . Duration Study : Subjects treat 12 month , unless disease progression unacceptable toxicity occur , subject withdraws , study discontinue . Number Subjects : A total 90 subject randomize 1:1 randomization ratio Study Population : Subjects 18 year age old CP Ph+ CML imatinib failure ave achieve suboptimal response 3 - 18 month ( 12 - 77 week ) treatment 400 mg/day imatinib monotherapy . Test Product , Dose Mode Administration , Duration Treatment : Subjects dasatinib arm begin treatment dasatinib oral dose 100 mg QD . One dose reduction 70 mg due toxicity allow . One dose escalation 140 mg allow specified circumstance . Reference Therapy , Dose Mode Administration , Duration Treatment : Subjects imatinib arm begin treatment imatinib oral dose 600 mg QD Doses imatinib escalate 800 mg patient inadequate response 3 month dose reduction imatinib permit case patient . Criteria Evaluation : Efficacy : - Primary Endpoint : CCyR rate 6 month randomization . - Secondary Endpoints : - MMR rate 3 , 6 , 12 month - CCyR rate 3 , 6 12 month - CHR rate 3 , 6and 12 month - Time to- , duration of- , MMR CCyR - Progression free survival ( PFS ) Safety : Adverse experience associate dasatinib imatinib treatment report treated subject . Adverse event assess continuously grade accord NCI Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 .</detailed_description>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Signed write informed consent , least 18 year old 2 . Adequate hepatic renal function 3 . Dasatinib na√Øve patient 4 . Patients cytogenetically and/or molecularly confirm Philadelphia chromosome BCRABL positive CPCML treat standard dose imatinib . 5 . ECOG status : 02 6 . And one follow criterion imatinib suboptimal response 1 ) CPCML patient fail achieve CHR 3 month MCyR 6 month therapy imatinib 400mg daily . 2 ) CPCML patient fail achieve CCyR 12 month imatinib 400mg daily 3 ) CPCML patient fail achieve MMoR ( less 3 log reduction ) 18 month imatinib 400mg daily 4 ) CPCML patient lose molecular response increase BCRABL 10 time regardless treatment duration . 1 . Concurrent malignancy 2 . Patients receive SCT 3 . Allergy hypersensitivity reaction study drug 4 . Female pregnant breast feeding . 5 . T315I mutation 6 . History significant bleeding disorder 7 . Women child bear potential 8 . Uncontrolled significant CVS disease : IHD . CHF 9 . Prior imatinib &gt; 400mg , imatinib &gt; 18 month 10 . Intolerance imatinib 400mg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>CML</keyword>
	<keyword>suboptimal response</keyword>
	<keyword>dasatinib</keyword>
	<keyword>imatinib</keyword>
</DOC>